Chris Polman, Free University of Amsterdam Abstract N Engl J Med 2006;345:899 Despite fears that natalizumab – which reduces progression in some categories of patients with multiple sclerosis &#
Chris Polman, Free University of AmsterdamAbstract N Engl J Med 2006;345:899Despite fears that natalizumab – which reduces progression in some categories of patients with multiple sclerosis – might increased the risk of a fatal viral infection, two-year randomised study finding have now given some reassurance that patients with relapsing disease can be treated.